These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23259554)

  • 1. Glucose and LDL lowering: the need for intensive therapy.
    Del Prato S
    Curr Vasc Pharmacol; 2012 Nov; 10(6):687-9. PubMed ID: 23259554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.
    Verma S; Leiter LA; Mazer CD; Bain SC; Buse J; Marso S; Nauck M; Zinman B; Bosch-Traberg H; Rasmussen S; Michelsen MM; Bhatt DL
    Circulation; 2018 Oct; 138(15):1605-1607. PubMed ID: 30354517
    [No Abstract]   [Full Text] [Related]  

  • 3. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
    Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
    Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.
    Bajaj M; Jialal I
    Metab Syndr Relat Disord; 2009 Apr; 7(2):79-81. PubMed ID: 19351292
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis.
    Masson W; Lobo M; Siniawski D; Molinero G; Huerín M; Nogueira JP
    High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):263-272. PubMed ID: 31313082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.
    Catapano AL
    Nat Rev Cardiol; 2018 Jan; 15(2):75-76. PubMed ID: 29336436
    [No Abstract]   [Full Text] [Related]  

  • 7. Diabetic dyslipidemia: extending the target beyond LDL cholesterol.
    Nicholls SJ; Lundman P; Tardif JC
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S20-4. PubMed ID: 20489416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy.
    van Stee MF; de Graaf AA; Groen AK
    Cardiovasc Diabetol; 2018 Jun; 17(1):94. PubMed ID: 29960584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].
    Pérez A; González Blanco C; Hernández-Presa MÁ; Chaves J
    Endocrinol Nutr; 2011; 58(6):283-90. PubMed ID: 21641286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials.
    Drexel H; Rosano GMC; Lewis BS; Huber K; Vonbank A; Dopheide JF; Mader A; Niessner A; Savarese G; Wassmann S; Agewall S
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):97-103. PubMed ID: 31298686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
    Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group
    Diabetes Care; 2016 Jul; 39(7):1089-100. PubMed ID: 27289122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyslipidaemia in type 2 diabetes mellitus: bad for the heart.
    Katsiki N; Tentolouris N; Mikhailidis DP
    Curr Opin Cardiol; 2017 Jul; 32(4):422-429. PubMed ID: 28362666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
    Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-intensity lipid-lowering regimens in patients with stable coronary artery disease: the intriguing question of all-cause mortality.
    Danchin N; Simon T
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):328-330. PubMed ID: 31539045
    [No Abstract]   [Full Text] [Related]  

  • 19. [Not Available].
    Bilz S
    Ther Umsch; 2017; 74(8):445-453. PubMed ID: 29461147
    [No Abstract]   [Full Text] [Related]  

  • 20. [Intensive blood glucose lowering to reduce cardiovascular risk: contra].
    Marx N
    Dtsch Med Wochenschr; 2009 May; 134(20):1061. PubMed ID: 19421930
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.